Kaufmanskinner0964

Arthropathy of the proximal interphalangeal joint (PIP) is common. Joint denervation is a symptomatic treatment. It relieves pain by cutting the afferent nerve branches without altering joint biomechanics, and is indicated in painful arthropathy with conserved range of motion. The objective of this study was to evaluate clinical outcome in PIP denervation and the sustainability of results.

Denervation is an effective intervention in painful PIP arthropathy with functional range of motion, showing lasting benefit.

A single-center retrospective study included all patients with painful PIP arthropathy with functional range of motion treated by denervation between January 2005 and September 2018 and evaluated by an independent examiner. Joint stiffness was an exclusion criterion. 54 consecutive denervation procedures were performed in 42 patients (41 women, 1 man) with a mean age of 66.5 years (range, 44-78 years). There were 11 inflammatory and 43 degenerative arthropathies.

The 42 patients were evaluated in consultation or contacted by telephone, with a mean follow-up of 51 months (range, 4-168 months). Mean VAS pain score was 7.5/10 (range, 5-10) before the procedure and 1.1/10 (range, 0-8) at last follow-up. Patients considered their joint cured or improved in 78% of cases whatever the etiology (42 cases/54), and in 86% of cases of degenerative arthropathy (37 cases/43). 32 patients were satisfied or very satisfied with the intervention (76% of cases). Active range of motion was improved in 16 cases, unchanged in 33 and impaired in 5. There were 7 denervation failures, which led to surgical treatment by fusion (2 cases) or joint replacement (5 cases); 5 of these cases concerned arthropathy of inflammatory origin.

Denervation is an effective treatment for painful PIP osteoarthritis, providing lasting pain relief while conserving range of motion.

IV; retrospective study.

IV; retrospective study.

To evaluate the diagnostic performance of simplified animal naming test (S-ANT1) for minimal hepatic encephalopathy (MHE) in patients with cirrhosis from a Chinese tertiary centre and to optimize the application strategy of S-ANT1 in clinical practice.

The Animal Naming Test 1 (ANT1) was performed in all included cirrhotic patients and healthy volunteers. S-ANT1 was calculated to adjust for age and education. Psychometric Hepatic Encephalopathy Score (PHES) was also performed in patients with cirrhosis.

88 cirrhotic patients and 34 healthy control subjects were included. Cirrhotic patients were characterized with lower S-ANT1 scores (P =  0.001). In patients with cirrhosis, score of S-ANT1 was correlated with PHES score, age, school education period, and blood ammonia (all P values <0.05). With ≤20 animals as the cut-off value, S-ANT1 could distinguish MHE and no MHE with a sensitivity of 77.5% and a specificity of 58.3%. A three-step screening strategy, with 90% as a threshold for sensitivity and specificity and two cut-off values "≤12 animals" and ">23 animals", was then formulated to rule out patients with high possibility of MHE and with high possibility of no MHE. The remaining "ruled-in" patients should be further evaluated for MHE using PHES.

S-ANT1 is an important screening tool for MHE in cirrhotic patients. The three-step screening strategy based on S-ANT1 and PHES is conducive to the identification of MHE in clinical practice.

S-ANT1 is an important screening tool for MHE in cirrhotic patients. The three-step screening strategy based on S-ANT1 and PHES is conducive to the identification of MHE in clinical practice.

Breast cancer is the leading cancer in women worldwide with about 2 million new cases and 685,000 deaths each year. Mammography is the most widely used screening and diagnostic method. Currently, digital technologies advances facilitate the development of connected and portable devices. To overcome some of the disadvantages of mammography (breast compression, difficulty in analyzing dense breasts, radiation, limited accessibility in some countries, etc.), portable devices, conventionally known as connected bras (CB), have been created to offer an alternative method to mammography. The objective of our review was to list all the published CBs in order to know their main characteristics, their potential indications and their possible limitations.

A bibliographical search in the PUBMED database selecting only articles written in French or English, between 2011 and 2020, found 7 CBs under development.

These CBs use thermal, ultrasonic and impedance sensors. Their advantages are an absence of irradiation, an absence of breast compression and a flexibility of use (outside an X-ray cabinet). Mammary gland analysis times vary, depending on the device, between 30min and 24h. They are all connected to data transmission systems and models that analyze the results.

These CBs are mostly still undergoing clinical validation (only [iTBra] has been evaluated in a clinical trial) and require evaluation steps that will eventually allow their future use for breast cancer detection in high-risk women, particularly in women with dense breasts and in women between screening waves.

These CBs are mostly still undergoing clinical validation (only [iTBra] has been evaluated in a clinical trial) and require evaluation steps that will eventually allow their future use for breast cancer detection in high-risk women, particularly in women with dense breasts and in women between screening waves.

Choroidal neovascularization (CNV) is a rare, but devastating cause of vision loss in children with the majority of current publications limited to small case series. Utilizing a large clinical registry allows us to understand the most common etiologies of this disease and visual outcomes.

Retrospective analysis.

Patients < 18 years in the IRIS® Registry diagnosed with pediatric CNV between 2013-2019.

Cases were identified based on ICD-9/10 diagnosis codes for CNV or CNV-related etiology, and current procedural terminology (CPT) treatment codes. We assessed the etiology of CNV, treatment patterns, and visual outcomes.

2,353 eyes with pediatric CNV were identified. The most common identifiable etiologies of pediatric CNV were posterior uveitis/inflammatory chorioretinal disease (19.4%), myopia (18.4%), hereditary dystrophy (5.4%), chorioretinal scar (4.2%), choroidal rupture (3.5%), optic nerve drusen (3.2%), osteoma (1.9%), and solar retinopathy (0.2%). In 38.2% of eyes, CNV was "idiopathic", and4, p <0.0001).

CNV is a rare, sight-threatening condition in children with the most common etiologies being "idiopathic", inflammatory chorioretinal disease, and myopia. Eyes undergoing treatment tended to be in older patients and had worse baseline VA compared to eyes that did not undergo treatment. Those that were treated experienced significant improvement in vision that was maintained long-term.

CNV is a rare, sight-threatening condition in children with the most common etiologies being "idiopathic", inflammatory chorioretinal disease, and myopia. Eyes undergoing treatment tended to be in older patients and had worse baseline VA compared to eyes that did not undergo treatment. Those that were treated experienced significant improvement in vision that was maintained long-term.We aimed to compare mitochondrial function, mitochondrial dynamics, apoptosis, and necroptosis between odontogenic cysts/tumors, including radicular cysts, dentigerous cysts, ameloblastoma, vs. dental follicles as control. We demonstrated that mitochondrial dysregulation and imbalanced mitochondrial dynamics were observed in ameloblastoma. Apoptosis was increased in dentigerous cysts, and ameloblastoma, while necroptosis was suppressed in ameloblastoma. Necroptosis in radicular cysts was higher than that of control, suggesting that the inflammation-associated cell death occurred in radicular cysts. Our findings suggest ameloblastoma exhibited mitochondrial dysfunction, decreased mitochondrial fusion, and potential apoptosis. Therefore, alleviating mitochondrial dysregulation and apoptosis may be novel-targeted therapy for odontogenic cysts and tumors.The aim of this study was to establish the potential effect of Laurus nobilis ethanolic extract on improving insulin sensitivity and protecting liver cells from apoptosis, mitochondrial dysfunction, oxidative stress (OS), and inflammation; all of which considered as major alterations occurring during insulin resistance (IR) as well as diabetes onset, in hyperinsulinemic and hyperglycemic-induced HepG2 cell line. Thereby, L. nobilis ethanolic extract has been first chemically characterized using LC-MS/MS technique. Subsequently, HepG2 cells were pre-treated with an optimal concentration of L. nobilis ethanolic extract for 24 h, and then, subjected to 30 mM D-glucose and 500 nM insulin mixture for another 24 h in order to induce hyperinsulinemia and hyperglycaemia (HI/HG) status. Several parameters such as biocompatibility, hepatotoxicity, reactive oxygen species (ROS), mitochondrial transmembrane potential, dynamics, and metabolism, multicaspase activity, glucose uptake, in addition to genes and proteins expression levels were investigated. The obtained results showed that the bioactive extract of Laurus nobilis increased the number of living cells and their proliferation rate, significantly attenuated apoptosis by modulating pro-apoptotic pathways (p21, p53 and Bax genes), allowed a relative normalization of caspases-activity, and decreased the expression of inflammatory markers including c-Jun, NF-κB and Tlr4 transcripts. L. Nobilis ethanolic extract reduced considerably total intracellular ROS levels in challenged HepG2 cells, and regulated the mitochondrial OXPHOS pathway, demonstrating the potential antioxidant effect of the plant. Ethanolic plant extract increased insulin sensitivity, since an elevated expression of master transcripts responsible for insulin sensitivity including IRS1, IRS2, INSR was found. Taken together, obtained data suggest that L. nobilis ethanolic extract offers new insights in the development of potential antioxidant, insulin sensitizing as well as hepatoprotective drugs.The oocyte is recognised as the largest cell in mammalian species and other multicellular organisms. Mitochondria represent a high proportion of the cytoplasm in oocytes and mitochondrial architecture is different in oocytes than in somatic cells, characterised by a rounder appearance and fragmented network. Although the number of mitochondria per oocyte is higher than in any other mammalian cell, their number and activity decrease with advancing age. Mitochondria integrate numerous processes essential for cellular function, such as metabolic processes related to energy production, biosynthesis, and waste removal, as well as Ca2+ signalling and reactive oxygen species (ROS) homeostasis. Further, mitochondria are responsible for the cellular adaptation to different types of stressors such as oxidative stress or DNA damage. When these stressors outstrip the adaptive capacity of mitochondria to restore homeostasis, it leads to mitochondrial dysfunction. MLi-2 chemical structure Decades of studies indicate that mitochondrial function is multifaceted, which is reflected in the oocyte, where mitochondria support numerous processes during oocyte maturation, fertilization, and early embryonic development. Dysregulation of mitochondrial processes has been consistently reported in ageing and age-related diseases. In this review, we describe the functions of mitochondria as bioenergetic powerhouses and signal transducers in oocytes, how dysfunction of mitochondrial processes contributes to reproductive ageing, and whether mitochondria could be targeted to promote oocyte rejuvenation.